
Opinion|Videos|May 29, 2024
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
Author(s)Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
3
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
4
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
5